Ribopro

Ribopro

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

RiboPro is a private, early-revenue stage CDMO and platform company focused on enabling mRNA-based therapeutics and vaccines. It provides a full suite of services from custom mRNA design and manufacturing to GMP production and LNP formulation, supported by its proprietary technology platforms. The company targets academic researchers, biotech startups, and pharmaceutical companies, positioning itself as a specialized partner in the rapidly growing RNA therapeutics sector. With a strong emphasis on quality, customer support, and internal R&D, RiboPro aims to accelerate the development of next-generation medicines.

RNA TherapeuticsBiologics

Technology Platform

Proprietary mRNA design (RIBOPERFECT™), immune-stealth mRNA technology (RIBOSTEALTH™), LNP formulation expertise, and GMP manufacturing platform (RiboFlux™).

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The massive and growing investment in mRNA therapeutics and vaccines creates sustained demand for specialized CDMO services.
The company's one-stop-shop model and licensable technologies position it to capture clients from early research through to clinical development, offering multiple revenue streams.

Risk Factors

Faces intense competition from large, scaled CDMOs and other mRNA specialists.
Revenue is dependent on the success and timelines of client projects, creating concentration risk.
Rapid technological evolution in RNA delivery and design requires continuous R&D investment to avoid obsolescence.

Competitive Landscape

Competes with large, diversified CDMOs (e.g., Lonza, Catalent) building mRNA capacity, other specialized mRNA service providers, and the internal development capabilities of large pharmaceutical companies. Differentiation is based on deep mRNA-specific expertise, proprietary technology, and a full-service, integrated offering.